| Identification | Back Directory | [Name]
2,3,5,6,7,8-HEXAHYDRO-1H-CYCLOPENTA[B]QUINOLIN-9-YLAMINE | [CAS]
62732-44-9 | [Synonyms]
Takinocrine
Brn 0475930
MFCD11052605
AKOS MSC-0106
AURORA KA-7699
Unii-cv71vtp0vn
CBI-BB ZERO/005050
8-Hexahydro-1H-cyclopenta[b]quinolin-9-ylaMine
2,3,5,6,7,8-Hexahydro-1H-cyclopenta[b]quinolin-9-
1H,2H,3H,5H,6H,7H,8H-Cyclopenta[b]quinolin-9-amine
2,3,5,6,7,8-Hexahydro-1H-cyclopenta[b]quinolin-9-amine
9-AMINO-2,3,5,6,7,8-HEXAHYDRO-1H-CYCLOPENTA[B]QUINOLINE
1H-Cyclopenta(B)quinolin-9-amine, 2,3,5,6,7,8-hexahydro-
2,3,5,6,7,8-HEXAHYDRO-1H-CYCLOPENTA[B]QUINOLIN-9-YLAMINE
9-Amino-2,3,5,6,7,8-hexahydro-1H-cyclopentaxinolina monohydrate
2,3,5,6,7,8-hexahydro-1H-cyclopenta[b]quinolin-9-amine hydrochloride
2,3,5,6,7,8-Hexahydro-9-amino-1H-cyclopenta(b)quinoline hydrochloride
2,3,5,6,7,8-hexahydro-1H-cyclopenta[b]quinolin-9-ylamine hydrochloride
2,3,5,6,7,8-hexahydro-1H-cyclopenta[b]quinolin-9-amine(SALTDATA: HCl H2O)
9-Amino-2,3,5,6,7,8-hexahydro-1H-cyclopenta(b)quinoline monohydrochloride
2,3,5,6,7,8-hexahydro-1H-cyclopenta[b]quinolin-9-amine hydrochloride hydrate
1H-Cyclopenta(b)quinoline, 2,3,5,6,7,8-hexahydro-9-amino-, monohydrochloride | [EINECS(EC#)]
676-166-9 | [Molecular Formula]
C12H16N2 | [MDL Number]
MFCD00618424 | [MOL File]
62732-44-9.mol | [Molecular Weight]
188.27 |
| Chemical Properties | Back Directory | [Melting point ]
202-203 °C(Solv: methanol (67-56-1); water (7732-18-5)) | [Boiling point ]
368.0±42.0 °C(Predicted) | [density ]
1.170±0.06 g/cm3(Predicted) | [storage temp. ]
-20°C | [solubility ]
DMF: 25 mg/ml,DMSO: 25 mg/ml,DMSO:PBS (pH 7.2) (1:3): 0.25 mg/ml | [form ]
A solid | [pka]
10.88±0.20(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Ipidacrine is used in biological studies as a possible treatment of toxic cognitive disorders. | [Definition]
ChEBI: 2,3,5,6,7,8-hexahydro-1H-cyclopenta[b]quinolin-9-amine is an aminoquinoline. | [in vivo]
Ipidacrine (1 mg/kg, p.o., repeated and a single dose for 5 days) by repeated administration has more potent antiamnesic effects than by single administration in induced by nucleus basalis of meynert (NBM) induced rats[1].
Ipidacrine (10 mg/kg p.o., a single dose) significantly decreases spontaneous movements, which is more selective as an antiamnesic than either Tacrine (HY-111338) and E-2020 (HY-B0034) in rats[1].
Ipidacrine (6.7 mg/kg, intragastrically, daily for 14 days) leads to statistically more efficient evolving of intracavernous pressure (ICPmax)/maxipressure (MAP) compared with control group in Streptozotocin (STZ) (HY-13753)-induced diabetic rats[3].
| Animal Model: | Rats[1] | | Dosage: | 1 mg/kg | | Administration: | p.o., repeated and a single dose for 5 days | | Result: | The repeated administration of ipidacrine improved amnesia induced by nucleus basalis of meynert (NBM) lesions in the passive avoidance task in rats. |
| Animal Model: | Rats[1] | | Dosage: | 3, 10, 30 mg/kg | | Administration: | p.o., a single dose | | Result: | Decreased pupil size and increased salivation at 3 mg/kg, decreased spontaneous movements at 10 mg/kg and decreased body temperature and induced tremor at 30 mg/kg in rats. |
| Animal Model: | Rats with streptozotocin (STZ) (HY-13753) induced diabetes mellitus-induced erectile dysfunction (DMED)[1] | | Dosage: | 6.7 mg/kg | | Administration: | crushed, suspended in 1% starch solution and administered intragastrically daily for 14 days | | Result: | Ipidacrine was as effective as sildenafil and could significantly improve DMED symptoms. |
| [storage]
-20°C |
|
|